Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

NCT00280878 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-Hodgkin's Lymphoma (CD20+)

Interventions

DRUG: gemcitabine
DRUG: vinorelbine
DRUG: ifosfamide
DRUG: rituximab

Sponsor

Bayside Health